Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to study the role of an active and well-tolerated non-platinum agent,
gemcitabine, in a combination regimen with pemetrexed in the first-line treatment of advanced
NSCLC. This study will serve to define the role of next generation agents in a new
combination regimen in the treatment of advanced NSCLC. This combination regimen may
ultimately be important in further expanding treatment options for patients while improving
survival, quality of life, and symptom control compared with platinum-based combination
regimens - and with acceptable toxicity.